StemCell Therapy

SHREVEPORT, La. -- Diabetic retinopathy is a complication of diabetes that affects the eyes.

Diabetes mainly affects the retina by causing poor blood flow and damage to the tiny, tiny blood vessels that supply the retina, that inner lining of the eye to that allows us to see, said Dr. Ashley Sipes, an ophthalmologist with Willis Knighton Health System.

It causes leakage of fluid and bleeding.

Also swelling, especially in the area of central vision. And that's one of the major causes of blindness from diabetic problems, Sipes explained.

High, uncontrolled blood sugar levels are what trigger the condition.

Its the hyperglycemia that does the damage. It basically kills the retina cells, or damages them, mainly from lack of oxygen, she said.

Sipes said diabetic retinopathy can happen to patients with all types of diabetes.

We not only have to watch our Type 1 diabetics, and Type 2 diabetics, but our gestational diabetics, we often forget about, she explained. Their bodies in pregnancies are even sometimes more sensitive to this damage. So, they need to be screened as well.

But Type 1 diabetics are at highest risk.

The Type 1 diabetics tend to be the most at risk just because usually theyve had it the longest, Sipes said.

Initially, patients may not have noticeable symptoms.

Almost half of my diabetics have some form of diabetic retinopathy, and the damage is off in the peripheral retina. And when I say that, I just mean not in the center of vision, but in the periphery, Sipes said. They're not going to have any symptoms.

If it is not treated, it becomes even more dangerous.

When somebody has vision loss from diabetes, thats typically that area of sharpest central vision. Its called the macula. And if it gets swollen from diabetes, it swells up like a sponge and cant do its job properly," Sipes said.

Diabetic retinopathy is not curable. But it is treatable. One treatment is an injection into the eye.

Theres a medicine called anti-VEGF that they inject that has been, gosh, one of the biggest breakthroughs in my lifetime, Sipes said. Theyre able to use that for not only diabetes, but in some cases also macular degeneration. It has been remarkable.

Other treatments include laser surgery and vitrectomy surgery.

But the best treatment is prevention and keeping diabetes and blood sugar under control.

Those yearly exams really are important to diagnose not only the diabetic retinopathy, but all the things that can happen associated with blood sugar," Sipes said.

View post:
Diabetic retinopathy can happen to patients will all diabetes types - KTBS

Eden Internal Medicine in Eden, North Carolina, believed it could up its game on treating diabetes and hypertension patients.

THE PROBLEM

For diabetes patients, first there was diabetes control and monitoring in between visits. Patients with uncontrolled diabetes with elevated A1c did not have any close monitoringbetween visits to bring the sugars down.

For example, if the patient has extremely high blood sugar in the three-months-average A1c test during the visit today, staff will not have a way of closely monitoring the patient in between the visits until the patient comes for the next visit in three months.

That means the patient has been uncontrolled or partially controlled for three months. Uncontrolled diabetes leads to many complications for the patient. CMS and other HEDIS star rating and quality metrics require better A1c control.

"There are limitations with Bluetooth technology," said Dr. Dhruv B. Vyas, owner and partner at Eden Internal Medicine. "Bluetooth is not convenient for the patients who are not technologically savvy and do not have a smartphone, which makes it difficult to monitor them for glucose control in between the visits.

"Bluetooth devices lead to failure to transmit sometimes and a problem with syncing the devices that results with more time spent by the staff and the patient to fix the device connectivity issues," he continued. "Many patients do not have smartphones or have aversion to technology, which limits the use of such devices."

Then there is patient accountability and compliance monitoring. It was difficult to manage patients' accountability and compliance without having instant blood glucose monitoring between the visits while they were at home.

"Some patients may need close monitoring of the blood sugar readings and monitoring to follow the diet and exercise program," Vyas explained. "Without the instant access to the blood sugar readings daily for the doctor's office, it is difficult to advise such patients to improve their lifestyle and/or make medication changes."

Then comes hypertension. First, there was monitoring of blood pressure in between the visits.

"Monitoring blood pressure in between visits and adjusting the medication to get the blood pressure to the goal is key," said Vyas. "Patients with uncontrolled blood pressure and recent medication changes require frequent office visits, which is difficult for many patients.

"And then there is managing the patient with white coat hypertension," he continued. "It is difficult to treat the patient with labile hypertension or white coat hypertension based on the readings in the office. Patients may have extremely high blood pressure in the office, but reportedly normal blood pressure at home."

Treating such patients aggressively may lead to a hypotensive episode and syncope, he added. Monitoring such patients with reliable devices would give accurate data in their home settings when they are comfortable and not anxious, he said.

Lack of reliability of the current cellular blood pressure devices also was an issue. Some of the existing cellular blood pressure devices were not as accurate, and it was difficult to treat patients based on those numbers. There was a need for reliable cellular blood pressure monitor devices that produce consistent readings based on which medication could be adjusted.

And again, limitations with Bluetooth technology.

"Bluetooth BP devices work for people with smartphones and who are technologically savvy, but do not work for people with a regular phone in a rural area and who have a phobia of technology," Vyas said.

PROPOSAL

Eden Internal Medicine turned to technology from Smart Meter. The technology offers cellular-connected devices like blood sugar and blood pressure machines that would instantly transmit the readings to a patient's records or to a dashboard.

"By using cellular technology, the patient barriers of technology reliance are removed," said Vyas. "Diabetic supplies and test strips can be automatically shipped to the patient's home when they run out of the strips by the intuitive data platform on Smart Meter technology. Unlimited amounts of test strips are supplied with the Smart Start program. The technology has excellent support staff for troubleshooting, which reduces patient and staff time.

"Smart Meter devices are reliable and accurate, and produce consistent results of the blood pressure and blood sugar readings, which are in acceptable norms of standard deviation," he added. "The technology enables flexible device distribution, including direct-to-patient delivery, and manages all device and data logistics. It also provides training and support for providers, patients and caregivers."

MARKETPLACE

There are numerous vendors of remote patient monitoring technology on the health IT market today. Healthcare IT News recently published a special report on RPM vendors. To read the detailed listings, click here.

MEETING THE CHALLENGE

Eden Internal Medicine integrated the Smart Meter technology with its AstuteDoc care management platform.

"The intuitive software from AstuteDoc provides dashboards, care plans, interventions, data graphs, time management, billing exports and many more features, along with dedicated care team members embedded in the medical practice," Vyas explained.

"AstuteDoc's complete care management solutions include chronic care management, remote patient monitoring, transition-to-care management, annual wellness, ACO quality metrics, incident-to-visit, and principal care management.

"This platform has been used by many ACO medical practices, PharmD, physicians, cardiologists, endocrinologists, primary care practices, nurse practitioners, care coordinators and medical assistants," he continued. "AstuteDoc embeds the PharmD or medical assistant into the doctor's offices to achieve care management goals and quality metrics."

Implementing the Smart Meter technology resulted in better workflow, seamless integration, and staff and patient satisfaction, Vyas reported.

"AstuteDoc's care management providers, staff and PharmD were able to deliver better outcomes for the patients' blood pressure and blood sugar control," he said. "This has translated into better HEDIS Star rating quality metrics.

"And patient compliance has significantly improved," he continued. "Care coordinators' intervention in between visits led to improvement in the patient lifestyle and accountability toward exercise and dietary choices. Patients were more knowledgeable about their health issues and more motivated to take care of their health."

Enrolling patients in remote monitoring was much easier for care coordinators using Smart Meter devices, he added. Instant transmission of the data and integration to the software was seamless and reduced enrollment time, he said.

"Monitoring of data was much easier for staff via specific alerts for each patient to achieve their goals," said Vyas. "During the pandemic, tele-visits were surging, and use of the Smart Meter devices nicely complemented with such visits to provide more data to the providers for the meaningful disease management. Home BP readings transmitted were used for certain visits like annual wellness, which is a required element for CMS."

RESULTS

On the diabetes metrics front, Eden Internal Medicine saw improvement in A1c readings, reducing hospitalizations via improved patient compliance.

"Improvement in A1c was noted on an average of 1.6 with patients at the next visit in three months," Vyas reported. "And there was significant improvement in postprandial hyperglycemia due to close monitoring and intervention between visits. This has translated into weight loss due to patient accountability and lifestyle change.

"By creating critical alert triggers for different glucose readings, we were able to reduce the hospitalizations for hypoglycemia and diabetic ketoacidosis," he continued. "In the long run, we expect this A1c control to reduce diabetes-induced complications."

Eden Internal Medicine achieved a 4.95 HEDIS Star Rating for United Healthcare Medicare.

On the hypertension metrics front, patients' blood pressure was reduced by intervention in between visits.

"Patients with labile hypertension or white coat hypertension had somewhat normal readings at home, which has been documented in the EHR," Vyas explained. "Remote patient monitoring blood pressure readings can be used one time a year during in-office visits for the CMS quality metrics goal of BP Control.

"There were two patients with syncopal episodes, which appeared to be due to low blood pressure readings at home with the same medications, while these patients were showing high BP readings in the office," he continued. "The number of medications was reduced now based on the home blood pressure readings to correct the problems of overmedication. Patients started having more energy, and had no syncopal episode and less medication expense."

ADVICE FOR OTHERS

"Any healthcare provider organization considering using similar technology needs to investigate cellular technology platforms that integrate with the care management software or EHR," Vyas advised. "Reliability of the device and consistent support from the vendor will be equally important for this program to be successful."

Vyas strongly advises against using Bluetooth technology unless patients are technologically savvy and have a smartphone. Providers should use remote patient monitoring technology for high-risk patients, set specific critical alerts and decide intervention/care plans to bring them to the desired goals, he added.

"For better implementation of the remote monitoring program, it needs to be intertwined with the other care management programslike CCM, TCM, AWV, PCM, etc., to maximize the benefit for the value-based patient care, which translates into better quality scores and outcomes," he said.

"Implementation for such programs is extremely difficult if you do not have dedicated staff or a care management company handling day-to-day needs of the program and critical alerts interventions as providers will not have time to handle the workload.

"And having a PharmD-supported program also provides significant value to the practice, patient, ACO and Medicare advantage plans," he concluded. "The highest performing practices achieve their goals from the most coordinated care team efforts, workflows and smart technology."

Twitter:@SiwickiHealthITEmail the writer:bsiwicki@himss.orgHealthcare IT News is a HIMSS Media publication.

Link:
Eden Internal Medicine reaps big rewards with RPM for diabetes and hypertension - Healthcare IT News

The Boston-based nonprofit T1D Exchange has been posing a Question of the Day to thousands of people living with type 1 diabetes (T1D) for nearly 10 years now. Questions run the gamut from How do you [dose insulin] for pizza? to Do you own a breath keytone meter? to Do you expect to take a device vacation for at least a few days this summer?

What a treasure trove of information the T1D Exchange must have amassed by now!

On first glance, this Question of the Day program looks to be a seamless and effective way for people who care about diabetes to ponder questions, share answers, see statistics, and interact with other like-minded folks all worthy and valuable functions.

But if you take a deeper dive into the T1D Exchange and this nearly decade-year old program, youll find much more than that.

The questions, answers, and much of the community that takes part in it constitute a living, breathing, thinking, and sharing database, helping not just one another, but to drive research to improve the lives of those with T1D across the board.

David Panzirer, trustee of The Leona M. and Harry B. Helmsley Charitable Trust funders of the T1D Exchange explained that those were their exact hopes for the Question of the Day program when it launched a decade ago. He worked on it with Dana Ball, program director of the T1D Program at the Helmsley Trust and former executive director of the Iacocca Foundation.

The real impetus was [when we looked around the diabetes research landscape] and thought, wheres the data? Panzirer told DiabetesMine.

The truth is, it did not exist in places most could access. It was off in vaulted places that no one else was willing to share, he said.

That meant researchers working on diabetes theories and treatments often had to add months, or even years, to their research timeline while they hunted down needed data. This contributed to why progress in the diabetes landscape seemed to come at a crawl, he said.

Today, the T1D Exchange, through both those Questions of the Day and their patient Registry that sprouted from that, now has treatment data and lifestyle information of about 30,000 people with diabetes. Of those, about 15,000 have opted to be part of their Registry, which seeks annual medical and other data and often asks members to participate in studies.

The T1D Exchange data culled from both of those sources has been presented in studies and programs around the world and continues to inform researchers, product manufacturers, and more on what the diabetes community needs.

All that data exists in one easy-to-access place, and is helping, many say, to speed up the process of research and bring new deliverables to market. Otherwise known as: improving the lives of people with diabetes.

And while doing all that heavy lifting, it also still continues to provide people with diabetes and those who care about them a place to chat, learn, vent, and adapt.

We use it as a platform to engage but also to share, T1D Exchange CEO David Walton told DiabetesMine. Its a great way to get [a large group of people] to respond.

Questions of the Day come from a variety of sources. The T1D Exchange team holds monthly brainstorming sessions, Walton said, to hone in on both what they may be wondering, what has bubbled up in the community at large, what companies and researchers may be curious about, and some staples, like the quarterly What is your A1C? question.

Anyone can opt in to respond, and much of the conversation, including tip sharing and support, happens online as each question is released.

That, Walton said, is where the support and sharing they know the community appreciates takes place.

Panzirer said it took them a solid 2 years and $20 million to get to the point of being a strong data collection program. From there, they both made that data accessible to researchers and other stakeholders and used it to begin what they really hoped to do: Push for faster, smarter and more impactful research and breakthroughs.

Their first step came when theyd only gathered about 10 percent of the group of respondents they have now.

With data from about 4,000 people, he said, they went before the Food and Drug Administration (FDA) and showed them two things: that the average A1C among their base was at 8.4 percent, and that 10 percent of the participants had experienced a severe diabetes event [blood sugar either low or high enough to require assistance, hospitalization, or both] in the past year.

I can tell you, their jaws were on the floor, Panzirer remembered of the FDA team. They had no idea. Now, we had clinical proof that the perception many had that insulin works fine and people with diabetes can easily do well with it wasnt a reality.

Without a doubt, he said, we were able to open their eyes and shine a light. It shined a light on just how poorly people were doing. We had the data to prove it.

To illustrate how this can culminate in helping people in real life and pushing research and industry to create life-bettering deliverables, Panzirer points to the success of Locemia Solutions.

Robert Oringer, an innovative businessman and the father of two sons with T1D, had an idea: What if emergency glucagon could be easier in every way: to carry, to administer, to store and more? After all, as the father of two sons with T1D, he knew well how bulky, stressful, confusing and even frightening the classic red case emergency glucagon rescue kits could feel.

He approached the T1D Exchange, who asked their community via Questions of the Day all about their feelings around rescue glucagon to confirm what Oringer saw. They jumped on board gathering data.

With that data and confidence in his product, they formed a committee of key opinion leaders like leading diabetes educator and author Hope Warshaw and well-known Yale endocrinologist Dr. William Tamborlane, and then went on to run clinical trials.

That data and study result information gave Locemia the platform to reach out to bigger names. Soon, the pharma giant Eli Lilly and Company took over the project.

Today, the product they created, the first-ever nasal glucagon Baqsimi, is available on the market, making carrying and using emergency glucagon a tremendously simpler, less stressful and more palatable option.

In other words, the data improved lives.

The timing of their first FDA meeting lines up, too, with the period of time when the FDA agreed to streamline the review process for continuous glucose monitors and after that, smarter insulin pumps and hybrid closed loop systems.

Today, just a decade past all of that seeming like a pipedream, new products are coming faster and faster.

The data that so many can access, Panzirer said, is a key reason why.

We forced a whole field to accelerate faster, he said. We forced the competition, and thats fueling more and more improvements.

While all this is going on, the questions continue to offer moral and educational support to thousands on a near daily basis, something Walton says they see as vitally important as well.

An example of how a question can help the community while informing researchers, T1D Exchange marketing manager Sarah Tackett told DiabetesMine, works like this:

They decided to ask the question, Do you brush your teeth after you treat a low?, after a dentist with a newly diagnosed child brought it up as a suggestion. This is an issue especially around nighttime lows, when people just want to go back to sleep after treating with sugar, but worry about damage to their teeth. Parents of children with T1D tend to be particularly worried.

The responses came in fast: 85 percent of respondents said they do not brush their teeth after treating a low.

From that came a hearty, helpful, and interesting discussion among respondents on the Question of the Day page on their website. People shared feelings on the topic, and asked for advice: Phew! Im not the only one! and Is there a better way?

It can be a very special thing to see folks connecting and helping one another around the questions, Tackett said.

They dont stop there, though.

We then send [the info] on to the research team, she said, so they can consider if there is anything to dig deeper into.

So, while the data may someday be important to a study, it becomes important the moment it sparks discussion, she said.

Questions can also give respondents a sense of power and input, she said. They may ask things like What features on a pump are most important to you? to help guide inventors and manufacturers toward what people want, an empowering experience for most.

Its a great springboard, Walton agreed.

The data also does another important thing, he said: It inspires bloggers and reporters to dig into topics that the public wants to learn more about or needs to hear more about.

In other words, increased education around diabetes is a byproduct as well.

As it celebrates 10 years, the T1D Exchange and its Registry and Question of the Day are far from done, said Walton.

They continue to collect data and welcome new people into their Registry with the goal of pushing things forward.

For Panzirer, who saw a second daughter diagnosed with T1D in 2017, it must and it shall move forward. He sees the same power today as he saw back when Ball suggested this to him long ago.

We are fortunate, Panzirer said. Dana was a visionary who got this whole thing rolling. I will be forever grateful to him.

Ball, who has retired from the role since, was the right person to partner with him to make this happen, he said.

Ive been a bull in a china shop. I told Dana Im not here to make friends. Im here to bring change. Are we successful in that? No, not until we dont have to use any of these [diabetes tools] anymore. And we will keep pushing until we are there, Panzirer said.

Go here to read the rest:
A Decade of Type 1 Diabetes 'Questions of the Day': What Have We Learned? - Healthline

Telehealth provider Teladoc Health is teaming up with The Ohio State University Wexner Medical Center to improve remote disease management for people with Type 2 diabetes.

Starting July 1, Wexner patients can enroll in Teladoc's Livongo for Diabetes Program, a patient-centric customized wellness program designed to improve hemoglobin A1c and other metabolic markers that reduce diabetes complications and ultimately reducing the use of healthcare resources.

The Livongo program focuses on sustainable behavioral changes that improve glycemic and HbA1c levels for patients. The program relies on real-time feedback, live coaching, curated educational content, health nudges, and five-day mini challenges for patients. The system eases data sharing with patients' physicians, allowing them to monitor their patients' progress.

Livongo patients will get a cellular-connected blood glucose meter, unlimited test strips, 24/7 interventional support, and ongoing access to Teladoc clinicians.

"With the prevalence of diabetes growing nationwide and in Ohio, patients are faced with ever-increasing challenges to manage this disease," Hal Paz, MD, executive vice president and chancellor for Health Affairs at The Ohio State University and CEO of the Ohio State Wexner Medical Center, said in a media release.

"This partnership with Teladoc Health's Livongo disease management and chronic care unit is a complementary platform to deliver high quality care to our patients living with diabetes while advancing our commitment to digital health and innovation," Paz said.

John Commins is a content specialist and online news editor for HealthLeaders, a Simplify Compliance brand.

See more here:
Teladoc, OSU Wexner, Tag-team on Diabetes Care Initiative - HealthLeaders Media

A new study shows that among older adults with non-valvular atrial fibrillation (NVAF), those with diabetes mellitus (DM) and osteoarthritis (OA) incur a higher risk of heart failure (HF) and other cardiovascular diseases (CVDs). The findings were published in BMC Public Health.

In this retrospective observational cohort study, researchers examined data of Hawaii Medicare inpatient, outpatient, and carrier claim files and beneficiary summary files from 20092017.

Overall, 19,588 patients were included in analysis; the population were divided into four mutually exclusive cohorts of DM/OA status: with both DM and OA (n=1,230), with DM only (n=4,659), with OA only (n=1,978), or without DM and OA (n=11,721), based on their diagnoses before baseline.

Among the population, patients with cardiovascular diseases (CVDs) were identified (stroke: diabetes n=837, osteoarthritis n=315, diabetes and osteoarthritisn=184, without diabetes and osteoarthritis n=1630)(AMI: diabetes n=438, osteoarthritis n=128, diabetes and osteoarthritisn=118, without diabetes and osteoarthritisn=603)(HF: diabetes n=2,254, osteoarthritis n=764, diabetes and osteoarthritis n=581, without diabetes and osteoarthritis n=4,272).

According to the results, after adjusting for age, sex, race/ethnicity, and other confounders, patients with both DM and OA had a higher risk for HF (HR=1.21 95% CI, 1.101.33) than those without DM and OA. Patients with both diseases also had a higher risk of HF than those with just OA. Those with diabetes had higher risks for all three cardiovascular diseases than the other three groups.

The study did have its limitations; one being that the severity of the CVDs and types of diabetes were not taken into account. Moreover, the CVD risks were analyzed without adjusting for biomarkers and other potential risk factors such as smoking and physical inactivity. Also, while diseases were identified from large data sets of patients with Medicare Part A & B, Part C claims were not included, thus, some misidentifications could exist, the researchers noted.

The researchers wrote that despite these limitations, the current study has several strengths. The use of a nine-year longitudinal dataset allowed more accurate CVD risk estimation compared with studies with cross-sectional data. Our data included a high proportion of non-White individuals, which also allowed the risk estimations for those minority groups that have been often overlooked in the past. Additionally, the use of Hawaii Medicare data enabled us to compare the variations in hazard ratios by DM/OA status based on all non-Health Maintenance Organization Medicare beneficiaries aged 65years or older with NVAF in Hawaii.

They added that the finding that older diabetic patients with NVAF would have additional risks for the CVDs will provide a new and useful public health perspective. Healthcare professionals may need to consider developing multifactorial interventions for older adults with NVAF tailored to different DM/OA statuses.

See more here:
Older AFib Patients with Diabetes and Osteoarthritis at Higher Risk of Cardiovascular Diseases - DocWire News

Managing type 2 diabetes typically involves losing weight, exercise and medication, but new research by Dr. Makoto Fukuda and colleagues at Baylor College of Medicine and other institutions suggests that there may be other ways to control the condition through the brain. The researchers have discovered a mechanism in a small area of the brain that regulates whole-body glucose balance without affecting body weight, which suggests the possibility that modulating the mechanism might help keep blood sugar levels in a healthy range.

A growing body of evidence strongly suggests that the brain is a promising yet unrealized therapeutic target for type 2 diabetes, as it has been shown that it can regulate glucose metabolism, said Fukuda, assistant professor of pediatrics-nutrition at Baylor. To further materialize this concept, it is of great interest to identify potentially druggable molecular targets mediating the brains antidiabetic effects.

Research has shown that within the hypothalamic region of the brain, a small area known as the ventromedial nucleus of the hypothalamus (VMH) contains glucose-sensing neurons and regulates glucose metabolism in peripheral tissues.

VMH neurons are thought to be crucial mediators of the neural glucoregulatory mechanism, Fukuda said. However, the signaling mechanisms within VMH neurons that mediate whole-body sugar control remain elusive. In this study, we identified a molecular pathway in the VMH that mediates whole-body glucose balance and involves Rap1, an enzyme known to mediate overnutrition-associated disorders.

The researchers worked with a diabetes model of high-fat diet-induced obesity in mice, in which they either activated or eliminated Rap1 specifically in VMH neurons by using either genetic or pharmacological techniques.

They discovered that activation of Rap1 in the hypothalamus exaggerated the high blood sugar levels or hyperglycemia in the diet-induced obesity mouse model. In contrast, genetic loss of hypothalamic Rap1 decreased hyperglycemia in dietary obesity.

Interestingly, the changes in glucose levels were observed without alterations in body weight, suggesting a primary role of Rap1 in glucoregulatory function, Fukuda said.

Our findings that Rap1 activity can be regulated via pharmacological intervention provide proof-of-concept for the potential of targeting Rap1 signaling within the brain to improve glucose imbalance and induce antidiabetic effects.

While having no effect on body weight regardless of sex, diet and age, Rap1 deficiency in VMH neurons markedly lowered blood glucose and insulin levels and improved glucose and insulin tolerance.

Taken together, the data suggest that hypothalamic Rap1 is a molecular pathway for the control of glucose metabolism and mediates high-fat diet-induced glucose imbalance, thereby making it a potential target for therapeutics.

If we gain weight, blood glucose seems to be disturbed. Thats why obese people may have diabetes, Fukuda said. But in this mouse model we discovered that by modulating the activity of Rap1 in a small brain area we could regulate whole-body glucose metabolism without body weight change. There is still much work to do, but our findings suggest that maybe in the future obese people with diabetes could lower blood sugar levels by manipulating this mechanism of Rap1 in the brain without having to lose weight.

Find all the details of this study in JCI Insight.

Other contributors to this work include Kentaro Kaneko, Hsiao-Yun Lin, Yukiko Fu, Pradip K. Saha, Ana B. De la Puente-Gomez, Yong Xu, Kousaku Ohinata, Peter Chen and Alexei Morozov. The authors are affiliated with one or more of the following institutions: Baylor College of Medicine, Kyoto University, Nagoya University, Cedars Sinai Medical Center, National Institute of Mental Health and Fralin Biomedical Research Institute at Virginia Tech Carilion.

Financial support for this project was provided by U.S. Department of Agriculture Current Research Information System 6250-51000-055, AHA-14BGIA20460080, NIH-P30-DK079638, NIH R01DK104901, and NIH R01DK126655; NIH awards R01DK093587 and R01DK101379; AHA-15POST22500012, the Uehara Memorial Foundation, Takeda Science Foundation and Japan Foundation for Applied Enzymology. Further support was provided by NIH awards R01MH120290, R01HL103868 and R01HL120947. This project was also supported in part by the Mouse Metabolic and Phenotyping Core at Baylor College of Medicine with funding from NIH UM1HG006348 and NIH R01DK114356.

By Ana Mara Rodrguez, Ph.D.

See original here:
Rap1 controls the body's sugar levels from the brain, regulating it may help manage diabetes - Baylor College of Medicine News

Rich in fiber, vitamins, minerals, and antioxidants, fresh fruit can be an excellent addition to a well-rounded diet (1).

However, certain types of fruit contain more sugar and calories than others. Furthermore, some fruits can cause side effects for people with health conditions like diabetes and acid reflux. These fruits can still be enjoyed, but in smaller serving sizes.

This article takes a closer look at the fruits highest in sugar and calories, plus the ones you may need to limit if you have diabetes or acid reflux.

Some types of fruit, both fresh and dried, are high in natural sugar. If youre aiming to reduce your intake of carbs or sugar, stick to small amounts when enjoying these.

Dates are known for their sweet, almost caramel-like flavor. Their dried versions are often enjoyed as-is for a handy snack or used as a natural sweetener in recipes.

Although theyre rich in antioxidants and micronutrients like potassium, copper, and magnesium, theyre also high in sugar and carbs (2, 3).

One cup (160 grams) of dried dates contains (3):

Some of the most common varieties of dried fruit include apples, raisins, apricots, figs, mangoes, pineapples, and cranberries.

Compared with their fresh counterparts, they generally contain more calories, carbs, and sugar per serving. Most varieties are also rich in fiber, potassium, and vitamin C (4).

Because of the high sugar content, its best to enjoy dried fruits in moderation, especially if youre looking to decrease your sugar intake.

A 1-cup (160-gram) serving of a dried fruit mixture contains (4):

Native to southeastern China, this tropical fruit is known for its unique taste and appearance.

It contains many key micronutrients, including vitamin C, copper, and potassium. Its also relatively high in sugar, which may be an issue if youre on a low carb or low sugar diet. (5).

One cup (190 grams) of raw lychees contains (5):

This delicious stone fruit is popular for its sweet flavor and soft, creamy texture.

Mangoes are also brimming with a variety of nutrients, including vitamin C, folate, and copper. On the other hand, they contain a high amount of natural sugar in each serving (6).

One cup (165 grams) of mangoes contains (6):

Many types of fruit are high in calories. While they can be enjoyed as part of a nutrient-dense, well-rounded diet, you may want to keep an eye on your portion sizes if youre trying to cut your calorie intake or lose weight.

Avocados are high in calories, thanks to their content of heart-healthy monounsaturated fats. Theyre also a good source of important vitamins and minerals like potassium, vitamin C, and B vitamins (7).

Plus, theyre loaded with fiber, an essential nutrient that can support regularity and digestive health (8).

One cup (150 grams) of avocado contains (7):

Shredded coconut is a common ingredient in baked goods, smoothie bowls, and breakfast dishes.

Although its rich in nutrients like manganese, copper, and selenium, its also high in fat and calories (9).

In particular, coconuts are high in medium-chain triglycerides (MCTs), a type of fat that is readily absorbed by your body. MCTs have been associated with several health benefits, including improved body composition and heart health (10).

One cup (93 grams) of dried unsweetened coconut contains (11):

Prunes are a type of dried fruit made from plums.

Because of their fiber content and laxative effects, theyre sometimes used as a natural remedy for constipation. However, like other types of dried fruit, theyre also relatively high in calories, carbs, and sugar. (12).

One cup (174 grams) of pitted prunes contains (13):

If you have diabetes, its important to eat plenty of nutrient-dense foods rich in fiber to support healthy blood sugar levels (14).

Meanwhile, foods that are low in fiber and high in added sugar should be limited, including certain forms of fruit (14).

Candied fruit is a type of fruit made by soaking and heating fruit in sugar syrup, resulting in a product with a sweet flavor and long shelf-life.

Not only is candied fruit high in calories and low in fiber, but it also packs a lot of sugar and carbohydrates into each serving. This may not be ideal for those with diabetes.

3.5 ounces (100 grams) of candied fruit contains (15):

Fruit juice offers a concentrated amount of carbs and sugar without any of the fiber found in fresh fruit. Many types also contain added sugar, which can negate many of the potential health benefits that the fresh versions otherwise provide.

In a review of four studies, increased intake of sugar-sweetened fruit juice was linked to a higher risk of type 2 diabetes (16).

Another study in 8,492 women found that drinking fruit juice was tied to increased levels of hemoglobin A1C, a marker that is used to measure long-term blood sugar control (17).

An 8-ounce (240-mL) serving of orange juice contains (18):

While canned fruit can be a quick and convenient way to squeeze a few servings of fruit into your diet, it may not be the best choice for those with diabetes.

This is because its generally higher in carbs and sugar and lower in fiber, compared with other types of fruit (19).

In particular, fruit canned in heavy syrup or juice is typically much higher in sugar than fruit canned in water. Thus, the water-canned version may be a better option when aiming to keep your blood sugar levels in check.

A 1-cup (214-gram) serving of fruit cocktail canned in heavy syrup contains (19):

Certain fruits may worsen symptoms for those with gastroesophageal reflux disease (GERD), also known as acid reflux (20).

Although these fruits are highly nutritious and can fit into a balanced diet, you may want to limit your intake if you find that they trigger symptoms of acid reflux.

Citrus fruits like oranges are loaded with essential nutrients like fiber, vitamin C, and potassium (21).

Unfortunately, theyre also highly acidic and may worsen heartburn for people with GERD.

One navel orange contains (21):

Although theyre often used as a vegetable in many recipes, tomatoes are technically classified as fruit.

This nutritious ingredient is rich in vitamin C, fiber, and lycopene a carotenoid that has been well studied for its antioxidant effects (22, 23).

However, like citrus fruits, the acidity of tomatoes and tomato-based products may trigger symptoms in people with GERD (24).

One cup (180 grams) of chopped tomatoes contains (22):

Grapefruit is a type of citrus fruit known for its tasty, tart, and slightly bitter flavor.

Its low in calories and rich in vitamins and minerals like vitamins A and C, potassium, and thiamine (25).

Unfortunately, grapefruit and grapefruit juice are also common symptom triggers for people with GERD (26).

A 1-cup (230-gram) serving of grapefruit contains (25):

Although fruit is highly nutritious and associated with many health benefits, some types especially dried, juiced, and canned versions may be high in sugar and calories.

Not only that, but certain kinds of fruit can increase blood sugar levels in people with diabetes or trigger symptoms in people with GERD.

Still, keep in mind that most fresh, minimally processed varieties of fruit can be enjoyed in moderation as part of a nutrient-dense, well-rounded diet.

The rest is here:
What Are the Most Unhealthy Fruits? Sugar, Calories, and More - Healthline

Five cancer cell therapies are approved in the U.S. Scores more are in clinical testing as drugmakers work to repurpose human cells as a platform for new medicines, many of which are similarly targeted at different types of cancer.

But more and more biotechnology companies aim to use cell therapy for diseases that turn the body's immune system against itself.

"We're in the era of engineering cells to do our bidding," said Samantha Singer, the CEO of a new startup launching Wednesday with $95 million in venture capital funding. "We should do this in autoimmune disease."

Over the past three years, Singer and scientists from Third Rock Ventures, the company's principal venture backer, Harvard Medical School, Massachusetts Institute of Technology and the National Institutes of Health have been studying that idea, work that led to the creation of the newly debuted company.

Called Abata Therapeutics, the startup plans to genetically engineer a type of regulatory immune cell to treat multiple sclerosis, Type 1 diabetes and an inflammatory disease called inclusion body myositis. If all goes well, Abata expects to have early clinical trial data on its lead therapy for MS by 2024 and to start clinical testing of treatments for the other two diseases by the end of 2025.

"Now is the time for Abata because the technology has evolved to a point where we can actually do some of the things that we were dreaming of two or three years ago," said Diane Mathis, a professor of immunology at Harvard Medical School and a co-founder of Abata, in a video announcing the company's launch.

The cells Abata chose to work with, called regulatory T cells, or Tregs, are a core part of the body's immune system. Crucially, they also possess many of the attributes Singer and the Abata team were looking for in a therapy.

"The ideal therapy would be something that acts locally, only in tissue that has an autoimmune pathology," said Singer, in an interview. "You'd want something that could counter multiple mechanisms of inflammation and promote repair. You'd want something that's durable. That's what a Treg does in your immune system."

Abata plans to engineer these Tregs with a cell receptor specifically designed to recognize antigens protein flags that act as triggers for an immune response associated with inflamed tissue.

"I like to think that we are simply taking advantage of this powerful, wise immune system that nature gave us," said Richard Ransohoff, a neurologist and partner at Third Rock who co-founded Abata, in an interview.

Abata plans to first target a progressive form of MS, a disease in which the immune system attacks the protective covering of nerve cells. There are many drugs now approved for relapsing forms of MS and one, Roche's Ocrevus, cleared for the primary progressive stage of the disease.

But for patients with progressive MS who no longer experience active relapses, there's no treatment option, according to Abata.

"Nodules of immune active cells have become lodged in corrugations of the brain and spinal space," said Ransohoff, who described the brain as a walnut, with alleys that can harbor those nodules.

"Ocrelizumab doesn't touch these nodules of inflammation that live in the central nervous system and are going to stay there after all the peripheral inflammation is removed," he added, using Ocrevus' scientific name.

Abata estimates there are about 45,000 patients in the U.S. who have progressive MS with non-relapsing disease and ongoing inflammatory tissue injury. The company plans to identify these patients using an MRI biomarker developed by NIH researcher Daniel Reich, who is a scientific adviser for Abata.

Along with Third Rock, Abata is also backed by ElevateBio, a richly funded and unusual biotech that mixes in-house research with a partnering business helping other companies manufacture complex cell therapies.

Lightspeed Venture Partners, Invus, Samsara BioCapital and the JDRF T1D Fund also invested in Abata through the Series A funding round led by Third Rock and ElevateBio.

Abata is not alone in attempting to build cell therapies around Tregs, but it appears to be one of the most well-funded. GentiBio, Quell Therapeutics, Sonoma Biotherapeutics, Coya Therapeutics and, most recently, TRexBio, have all launched in recent years with plans to use Tregs to treat autoimmune diseases.

Originally posted here:
Third Rock-backed startup launches to develop cell therapies for MS, diabetes - BioPharma Dive

As we reach what seems to be the end of the deadly second wave of Covid-19 in India, several recovering patients stare at a long haul of dealing with persisting symptoms now being defined as long Covid by doctors. In light of the situation, News18 will run a 15-day series Decoding Long Covid where doctors with different specialisations will address concerns, recommend ways to deal with them, and suggest when to seek help.

In todays column, Dr Sweta Budyal, senior consultant endocrinologist at Fortis Hospital Mulund in Mumbai, explains why recovering patients may experience a new onset of diabetes, viral thyroiditis and a flare-up of autoimmune diseases.

In an interview with News18, Dr Budyal said, By now, it is common knowledge that diabetes increases the risk of Covid-19. But, in terms of long Covid, what we have been seeing is that it becomes considerably difficult to manage pre-existing diabetes in patients, during the recovery phase.

More importantly, patients who have never had diabetes, or do not have the risk factors associated with the disease, also turn diabetic post-Covid. So, Covid induces diabetes in some cases, and it can happen long after the use of steroids have stopped, she added.

Apart from diabetes, one of the symptoms of Covid patients is sick euthyroid, which is abnormalities in the development of thyroid hormones during any acute illness. It has been observed that during the recovery phase, too, several thyroid-related issues crop up. Some patients experience subacute thyroiditis or viral thyroiditis, which are characterised by more pronounced symptoms like fever, throat or neck pain. Such conditions can last from anywhere between eight to twelve weeks and may even require supportive treatment, said the doctor.

Thirdly, many patients also face autoimmune issues during the recovery phase. We have seen a trend in the increase of type 1 diabetes following covid in children. I have also come across a rare case of insulin autoimmune hypoglycemia syndrome, said Budyal. The doctor said that while there are also reports that the virus has been extracted from testicles and other endocrine organs, in those cases, longer implications post-recovery is yet to be studied.

As far as metabolism is concerned, most covid patients generally tend to lose weight, which they regain after the infection. Covid causes poor health which may also require a step down in the Blood Pressure medication doses in some cases, she explained.

The doctor said every physical change needs to be monitored closely while dealing with long Covid, and there is a need to stay in touch with a physician who will help you navigate this phase.

Read all the Latest News, Breaking News and Coronavirus News here

View original post here:
Decoding Long Covid: Viral Thyroiditis, Covid Induced Diabetes are Real Threats - News18

Bachem, a supplier to pharmaceutical and biotechnology companies worldwide, is celebrating its 50th anniversary this month. We take a look at the Swiss company'shistory.

Bachem is founded by entrepreneur Peter Grogg in Liestal, a small town near Basel in Switzerland. Grogg started the firm with just two employees, and with a focus on peptide synthesis - peptides are composed of amino acids that have a variety of functions treating health conditions such as cancer and diabetes.

Bachem moves its headquarters to the Swiss town of Bubendorf,with eight employees. In 1978 the company produces peptides for use in medicines for the first time. In 1981 production capacity triples and the workforce grows to 150.

The company expands into the US with Bachem Bioscience, Inc. in Philadelphia. To strengthen its presence in Europe, Bachem opens sales and marketing centres in Germany in 1988.

Further sales centres open in France in 1993. By 1995 the company employs 190 people. In 1996 it acquires the second largest manufacturer of peptides in the world and forms Bachem California with a site in Torrance.

Bachem company goes public and lists shares on the Swiss Stock Exchange. Further acquisitions include Peninsula Laboratories, Inc, based in California, and Sochinaz SA, a Swiss-based manufacturer of active pharmaceutical ingredients. By 2001, the company has 500 employees and sales reach 141 million CHF.

In 2003 the organisation is given a new legal holding structure to support its continued growth, which remains in place to this day.

Bachem acquires a brand by Merck Biosciences for ready-to-use clinical trial materials and related services.

In 2013, together with GlyTech, Inc. Bachem announces the development of a new amino acid that can help to treat multiple sclerosis, with a world market of more than $4 billion.

In 2015 it acquires the American Peptide Company (APC), which becomes integrated into Bachem Americas.

In 2016 the group opens a new building dedicated to R&D projects and small series production in Bubendorf. With a total of 1,022 employees, the workforce exceeds the 1,000 mark for the first time in the companys history. Sales are over the 200 million mark for the first time at 236.5 million CHF.Bachem expands into Asia with the establishment of a new company in Tokyo called Bachem Japan K.K.

By 2019 Bachem has a growing oligonucleotide portfolio - these are DNA molecules used in genetic testing, research, and forensics. It is hoped this will become a significant product range in the future.

Despite the COVID-19 pandemic, Bachem secures its supply of active ingredients, and even increases it in critical areas. Sales exceed the 400 million Swiss franc mark for the first time, and 272 new employees are hired.

Bachem celebrates its 50th anniversary and position as a global leader in the manufacture of peptides. While it remains headquartered in Bubendorf, the company employs 1,500 people at six locations worldwide. In the next five years there are plans to continue expanding.

Commemorating the company's anniversary, Kuno Sommer, Chairman of the Board of Directors, said: "Bachem's exceptional success story from a small laboratory to a global market leader is closely linked to Peter Grogg's values, and has been shaped by innovation, consistent quality and cost awareness, as well as by entrepreneurial vision."

Read the original:
Dexcom: changing the lives of people with type 1 diabetes | Medical Devices & Pharma - Healthcare Global - Healthcare News, Magazine and Website

FOR IMMEDIATE RELEASE:June 22, 2021

MEDIA CONTACTS:Dan Tierney: 614-644-0957 Breann Almos: 614-644-0957

Governor DeWine Signs Bills Into Law

(COLUMBUS, Ohio)Ohio Governor Mike DeWine today was joined by Senate Bill 21 sponsors and several stakeholders for a bill signing at the Ohio Statehouse.

Senate Bill 21, sponsored by Senator Nickie Antonio and Senator Nathan Manning, requires the Board of Emergency Medical, Fire, and Transportation Services to adopt guidelines for the assessment, triage, and transport of stroke patients to hospitals. The bill requires emergency service organizations to establish stroke protocols and provide training based on the boards guidelines.

Following the ceremony in private, Governor DeWine signed Senate Bill 42, sponsored by Senator Tim Schaffer, into law. The bill establishes the second week of November as Ohio Diabetes Awareness-Heart Connection Week to raise public awareness about the connection between diabetes and cardiovascular disease.

30

Continue reading here:
Governor DeWine signs bills for stroke protocols, public awareness for diabetes and cardiovascular disease - Ohio Department of Health

In his recently-published memoir, Making Excellence a Habit, Dr V Mohan recalls his experience of setting up one of the worlds largest chains of diabetes centres, Dr Mohans Group of Diabetes Institutions that began as a single clinic in 1991 and now has over 52 branches across 32 cities.

Dr V Mohan began researching on diabetes with his father, Prof. M. Viswanathan, when he was just 18.

India is home to 77 million people with diabetes and 80 million people with prediabetes. By 2030, the diabetic population in the country is close to hitting the mark of 101 million. Studies show that almost every Indian past the age of 50 is a diabetic unless proven otherwise, and at this rate it could become the next diabetes capital of the world soon, overtaking China. Dr V Mohan, who has done some stellar work over the last five decades in

BY

ET Online

AbcSmall

AbcMedium

AbcLarge

Introductory Offer

99 for 2 months

Then 2,499 for 1 year (208 per month)

Subscribe Now

(Credit card mandatory)

You can cancel your subscription anytime

Yearly

2499

15 Days Trial

Subscribe Now

(Pay Using Netbanking/UPI/Debit Card)

399/month

Monthly PLAN

Billed Amount 399

208/month

(Save 49%)

Yearly PLAN

Billed Amount 2,499

15 Days Trial +Includes DocuBay and TimesPrime Membership.

150/month

(Save 63%)

2-Year PLAN

Billed Amount 3,599

15 Days Trial +Includes DocuBay and TimesPrime Membership.

Already a Member? Sign In now

Special Offer on ET Prime

Subscribe to ET Prime - Get Flat 20% Off

Special Offer on ET Prime

Subscribe to ET Prime - Get Flat 25% Off

Special Offer on ET Prime

Subscribe to ET Prime - Get Flat 25% Off

Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors

Stock analysis. Market Research. Industry Trends on 4000+ Stocks

Clean experience withMinimal Ads

Comment & Engage with ET Prime community

Exclusive invites to Virtual Events with Industry Leaders

A trusted team of Journalists & Analysts who can best filter signal from noise

The rest is here:
'In India, 50% people with diabetes are not even aware they have the condition' - Economic Times

Photo: Photo of Artem Podrez in Pexels / Pexels

Diabetes is an issue that will never go unnoticed. Especially in recent years that we have had the opportunity to have more information and thus worry more about our health. The truth is that it is one of the most alarming chronic diseases today: it contributes to 10-15% of deaths in the United States. In addition, there are updated data from the World Health Organization (WHO), in which it is confirmed that in 2019 diabetes was the direct cause of 1.5 million deaths.Also the total of cases is increasing, it is estimated that almost 1.6 million Americans are diagnosed with diabetes each year. As if that werent enough, recent research led by the Johns Hopkins Bloomberg School of Public Health found disappointing data: the percentage of American adults with diabetes who achieved glycemic control it worsened between 2007 and 2010, and again between 2015 and 2018.

As expected, these findings come to emphasize even more (especially after a year of pandemic), the continuing challenges that arise in the control of diabetes. According to the study authors, it is time to take more control of the situation, it is no joke to say that diabetes is one of the most prevalent health conditions and in many cases it is directly related to controllable factors. The team used data from an annual government-sponsored health study to assess trends in blood sugar control among adults with diabetes, as well as the control of blood pressure and cholesterol.

It is well known that type 2 diabetes is the most common form of the disease and is strongly related to diet and lifestyle factors. According to the study, it is estimated that affects more than 13% of the adult population in the United States and it increases the risks of other serious diseases, especially cardiovascular ones. Based on this, traditional approaches to diabetes care are aspects focused on reducing chronic high blood sugar / glucose, maintaining blood pressure below levels considered hypertension and good cholesterol control. . In addition to aspects related to lifestyle; Unfortunately the study shows that most people do not have this disease under control.

According to information released in the study: the proportion of adults with glycemic control improved between 1999 and 2007, but then it fell from 57.4% to 50.5% between 2007 and 2018. In addition, the study authors also observed a decrease in the proportion of people who achieved blood pressure control. It is worth mentioning that the proportion that achieved adequate cholesterol control stabilized.

Elizabeth Selvin, lead author of the study and professor in the Department of Epidemiology at the Bloomberg School, stated in the press release that it is rather disturbing findings. There has been a real decline in glycemic control over the past decade, and overall, only a small proportion of people with diabetes are simultaneously meeting the key goals of glycemic control, blood pressure control, and high cholesterol control.

The researchers had access to data including interviews and clinical examinations of approximately 5000 people nationwide. The sample consisted of 6,653 survey participants from 1999 to 2018 who were at least 20 years old, not pregnant, and reported having been diagnosed with diabetes outside of pregnancy.

Among the most relevant data that occurred between 1999 and 2010: the percentage of respondents who achieved glycemic control, defined as HbA1c levels below 7.0%, increased from 44% to 57.4%. However, it dropped dramatically between 2015 and 2018. Something similar happened with blood pressure: it rose steadily from 64% between 1999 and 2002 to 74.2% between 2011 and 2014, then fell to 70.4% between 2015 and 2018. Finally, the percentage of people with diabetes who controlled their lipoprotein cholesterol high-density (non-HDL) increased from 25.3% between 1999 and 2002 to 52.3% between 2007 and 2010, but then reached only 55.7% between 2015 and 2018.

In conclusion, the researchers discovered that the proportion of people who managed to control the 3 risk factors increased from 9% between 1999 and 2002, to 24.9% between 2007-2010. And then it was reduced to 22.2% between 2015 and 2018. Another of the authors who led the study Michael Fang spoke about it, who stated that the trends uncovered in the study are a wake-up call. Well, they point out that millions of Americans with diabetes have a higher risk of serious complications, that is, the study suggests that the worsening of diabetes control may already be having a detrimental effect at the national level.

Another highly relevant aspect suggested by the studys findings is that something changed since 2010 and that it had an influence by delaying progress in controlling diabetes risk factors. Based on this, the researchers undertook the task of analyzing two large clinical trials, published in 2008. In which they found that the intensive reduction of HbA1c to very low levels did not lead to the cardiovascular benefits that people expected, and some trial participants saw a increased risk of hypoglycemia. It is worth mentioning that to date things have changed, that is, it was in 2008 when the results of these trials were published; today the market offers numerous new and improved diabetes medications. Which if they allow reducing HbA1c (glycosylated hemoglobin test, a blood test for type 2 diabetes and prediabetes) and without causing hypoglycemia.

Although much research work remains to be done, these types of studies come to give greater clarity to medical personnel and enrich strategies in the management of diabetes. Which should not only be focused solely on one optimal glycemic control of patients with diabetes, it is necessary to integrate the good management of risk factors, make adjustments in lifestyle, diet, stress levels and sleep cycles.

It may interest you:

eldiariony.com

See more here:
Diabetes: why Americans have such a hard time controlling blood sugar - The Saxon

Lille, France; Cambridge, MA; June 23, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced it will be making two poster presentations at two internationally-renown scientific and medical events in June 2021, including a thought-leadership documentary featuring Key Opinion Leaders (KOLs).

A poster presentation looking at the effects of age on the clinical performance of GENFITs proprietary diagnostic technology NIS4 in diagnosing at-risk NASH in patients with type 2 diabetes in comparison to a number of non-invasive tests, will be presented at the International Liver Congress 2021 on June 23-26, 2021, organized by the European Association for the Study of the Liver (EASL).

A poster presentation providing key insights into the performance of NIS4 technology either alone or in combination with other blood-based non-invasive tests in identifying at-risk NASH and advanced fibrosis in patients with and without type 2 diabetes, will be presented at the 81st Scientific Sessions of the American Diabetes Association (ADA) on June 25-29, 2021.

In addition, GENFIT is a key contributor to a thought-leadership documentary for ADA TV discussing, alongside KOLs, the link between NASH and patients with type 2 diabetes and how access to non-invasive diagnostic test kits to diagnose NASH, such as NASHnext, powered by GENFITs NIS4 technology, could provide an alternative to costly and invasive procedures and potentially benefit millions of patients. Featured KOLs include:

To view the 5-minute thought-leadership documentary, please click on the following link: https://www.youtube.com/watch?v=MlBoAG5tFMEv

Both events will be held virtually and the full programs can be found on the American Diabetes Association website and on the International Liver Congress website.

POSTER PRESENTATIONS

International Liver Congress June 23-26, 2021

Title: In Type 2 Diabetic Patients, the Identification of At-risk Nash is Impacted by Age: A Comparison of Serum-Based NITS Including NIS4

Abstract number: 2739

Poster identifier: PO-2739

Authors: Vlad Ratziu, Jeremy Magnanensi, Sylvie Deledicque, Elodie Delecroix, Yacine Hajji, Christian Rosenquist, Suneil Hosmane and Arun Sanyal.

81st Scientific Sessions of the ADA

Title: Application of NIS4 Technology for Stand-alone and Sequential Identification of At-risk NASH or Advanced Fibrosis in Non-Diabetic and Type 2 Diabetic Patients

Abstract number: #2021-A-5594-Diabetes

Poster number: 1174-P (Category 21-C Integrated PhysiologyLiver)

Authors: Christian Rosenquist, Yacine Hajji, Jrmy Magnanensi, Nicolas Stankovic-Valentin, Suneil Hosmane and Arun J. Sanyal

ABOUT THE INTERNATIONAL LIVER CONGRESS

The International Liver Congress is an annual congress and EASLs flagship event, attracting scientific and medical experts from around the world to learn about the latest in liver research.

ABOUT THE ADA

The ADA is the US leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive. It holds annual scientific sessions to bring together the latest, cutting-edge advances in diabetes research, prevention and care.

ABOUT NIS4

NIS4 is GENFITs non-invasive, blood-based diagnostic technology, which was developed to identify patients with non-alcoholic steatohepatitis (NASH) and significant to advanced fibrosis (F>2), also referred to as at-risk NASH. In January 2019, GENFIT signed a licensing agreement with Labcorp to make NIS4 technology available for use in clinical research through their drug development subsidiary, Covance. In September 2020, GENFIT signed another licensing agreement with Labcorp to commercialize NIS4 in the US and Canada as a Laboratory Developed Test. Since April 2021, Labcorp has made NASHnext, powered by NIS4, available for use in the clinic. GENFIT also continues to explore opportunities to obtain formal marketing authorization of an in vitro diagnostic (IVD) test supported by NIS4 technology in both the U.S. and European markets. For more information, please visit: https://nis4.com.

ABOUT NASH

NASH is a liver disease characterized by an accumulation of fat (lipid droplets), along with inflammation and degeneration of hepatocytes. The disease is associated with an increased risk of cardiovascular disease along with long-term risk for progression to cirrhosis, leading to liver insufficiency and potential progression to liver cancer. NASH is a serious disease that often carries no symptoms in its early stages, but if left untreated can result in cirrhosis, cancer, and the need for liver transplant. The prevalence of NASH is rapidly increasing as a result of the growing obesity and diabetes epidemics and is believed to affect as much as 12 percent of people in the U.S. and six percent worldwide.

ABOUT GENFIT

GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with cholestatic and metabolic chronic liver diseases. GENFIT is a pioneer in the field of nuclear receptor-based drug discovery, with a rich history and strong scientific heritage spanning more than two decades. GENFIT is currently enrolling in ELATIVE, a Phase 3 clinical trial evaluating elafibranor in patients with Primary Biliary Cholangitis (PBC). Elafibranor is an investigational compound that has not been reviewed and has not received approval by any regulatory authority. As part of GENFITs comprehensive approach to clinical management of patients with liver disease, the Company is also developing NIS4, a new, non-invasive blood-based diagnostic technology which could enable easier identification of patients with at-risk NASH. GENFIT has facilities in Lille and Paris, France, and Cambridge, MA, USA. GENFIT is a publicly traded company listed on the Nasdaq Global Select Market and on compartment B of Euronexts regulated market in Paris (Nasdaq and Euronext: GNFT). http://www.genfit.com

GENFIT FORWARD LOOKING STATEMENTS

This press release contains certain forward-looking statements with respect to GENFIT, including those within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the performance of NIS4 technology in the detection of NASH and at-risk NASH in non-diabetic and type 2 diabetic patients, the performance of NIS4 technology relative to other technologies, the potential for diagnostic tests powered by NIS4 technology to play a critical role in the diagnosis and management of patients with NASH, the potential for non-invasive testing to gain importance and the capability of NIS4 technology to identify patients who may require medical intervention, the development plans for NIS4 in the U.S. and in Europe and timing of such development plans, and the potential to obtain formal marketing authorization of an IVD test supported by NIS4 technology in the U.S. and/or European markets. The use of certain words, including consider, contemplate, think, aim, expect, understand, should, aspire, estimate, believe, wish, may, could, allow, seek, encourage or have confidence or (as the case may be) the negative forms of such terms or any other variant of such terms or other terms similar to them in meaning is intended to identify forward-looking statements. Although the Company believes its projections are based on reasonable expectations and assumptions of the Companys management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including in relation to safety, biomarkers, progression of, and results from, its ongoing and planned clinical trials, review and approvals by regulatory authorities of its drug and diagnostic candidates, exchange rate fluctuations and the Companys continued ability to raise capital to fund its development, as well as those risks and uncertainties discussed or identified in the Companys public filings with the French Autorit des Marchs Financiers (AMF), including those listed in Chapter 2 Main Risks and Uncertainties of the Companys 2020 Universal Registration Document filed with the AMF on 23 April 2021 under n D.21-0350, which is available on the Companys website (www.genfit.com) and on the website of the AMF (www.amf-france.org) and public filings and reports filed with the U.S. Securities and Exchange Commission (SEC) including the Companys 2020 Annual Report on Form 20-F filed with the SEC on April 23, 2021. In addition, even if the Companys results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this document. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.

CONTACT

GENFIT | Investors

Tel: +1 (617) 714 5252 | investors@genfit.com

PRESS RELATIONS | Media

Stephanie Boyer Press relations | Tel: +333 2016 4000 | stephanie.boyer@genfit.com

GENFIT | 885 Avenue Eugne Avine, 59120 Loos - FRANCE | +333 2016 4000 | http://www.genfit.com

Excerpt from:
GENFIT presents new NIS4 data in NASH at the International Liver Congress and the 81st Scientific - GlobeNewswire

Led by John Buse, MD, PhD, and Anna Kahkoska, MD, PhD, this analysis showed that GLP1-RA and SGLT2i medication use for type 2 diabetes of hospitalized COVID-19 patients was associated with lower odds of mortality and other adverse outcomes.

CHAPEL HILL, NC Diabetes is one of the comorbidities most strongly associated with severe coronavirus disease 2019 (COVID-19) in the United States, and data from early in the pandemic suggested individuals with type 2 diabetes faced twice the risk of death from COVID-19, as well as a greater risk of requiring hospitalization and intensive care.

The National COVID Collaborative (N3C), a partnership of NIH Clinical and Translational Science Award Program hubs, conducted a study of data from 12,446 individuals with type 2 diabetes who had a positive test for COVID-19 in 2020. These scientists found that individuals who had been treated with certain kinds of diabetes medications fared better than those who were treated with a different type of medication.

This research was published in Diabetes Care, the journal of the American Diabetes Association. The senior author is John Buse, MD, PhD, Co-Director of the North Carolina Translational and Clinical Sciences (NC TraCS) Institute at UNC and lead of the UNC Diabetes Research Center. The first author is Anna Kahkoska, MD, PhD, assistant professor in the UNC Department of Nutrition at the UNC Gillings School of Global Public Health and the UNC School of Medicine.

Two classes of medications that lower blood sugar glucagon-like peptide 1 receptor agonists (GLP1-RA) and sodiumglucose cotransporter 2 inhibitors (SGLT2i) have been associated with a reduction of cardiorenal events and mortality in previous large trials of cardiovascular, heart failure, and renal outcomes, in populations at high risk of cardiorenal events. Benefits associated with these medications appear most pronounced among individuals with type 2 diabetes and comorbid cardiovascular disease, heart failure, chronic kidney disease, and obesity, conditions that also incur the highest risk for severe COVID-19.

Additionally, scientists have speculated about plausible mechanisms for the protective effects of GLP1-RA and SGLT2i in COVID-19, independent of their glycemic effects. Yet, it is not known how the use of new medications is associated with severity of COVID-19.

Our objective was to characterize the association of premorbid use of GLP1-RA and SGLT2i with COVID-19 outcomes, said Buse, who is the Verne S. Caviness Distinguished Professor of Medicine and endocrinology division chief at the UNC School of Medicine. The study hypothesis was that use of both classes of medications would be associated with improved outcomes in the setting of COVID-19 infection. And characterizing these associations could reveal treatment strategies to improve outcomes for a population at high risk for COVID-19associated mortality.

For the study, the researchers selected individuals using dipeptidyl peptidase 4 inhibitors (DPP4i) as a comparator group to individuals taking GLP1-RA or SGLT2i medications because DPP4i medications can also be considered for second-line use after the initiation of metformin and have been suggested to be safe or beneficial in COVID-times in other real-world analyses.

To determine the respective associations of premorbid glucagon-like peptide-1 receptor agonist (GLP1-RA) and sodiumglucose cotransporter 2 inhibitor (SGLT2i) use, compared with premorbid dipeptidyl peptidase 4 inhibitor (DPP4i) use, with severity of outcomes in the setting of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

Of the 12,446 individuals, the 60-day mortality was 3.11%, with 2.06% for GLP1-RA use, 2.32% for SGLT2i use, and 5.67% for DPP4i use. Both GLP1-RA and SGLT2i use were associated with lower 60-day mortality compared with DPP4i use. Use of both GLP1-RA and SGLT2i medications was also associated with decreased total mortality, emergency room visits, and hospitalizations, though the individuals taking DPP4i medications were older and generally sicker.

N3C is a COVID research platform funded by the National Institute of Healths National Center for Advancing Translational Sciences (NCATS) including data on over 2 million people with a positive COVID test.The North Carolina Translational and Clinical Sciences (TraCS) Institute played an integral role in the development of N3C and supports efforts to use the data to develop better treatment and prevention programs for COVID.

Other authors of the Diabetes Care paper are Trine Julie Abrahamsen, G. Caleb Alexander, Tellen D. Bennett, Christopher G. Chute, Melissa A. Haendel, Klara R. Klein, Hemalkumar Mehta, Joshua D. Miller, Richard A. Moffitt, Til Strmer, and Kajsa Kvist.

Read the original post:
UNC Researchers Lead Study of Diabetes Treatment of Severely Ill COVID-19 Patients | Newsroom - UNC Health and UNC School of Medicine

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the launch of the nCounter Stem Cell Characterization Panel for the analysis and optimization of stem cell lines used in the development of potential novel therapeutics.

Recent breakthroughs in stem cell therapy, regenerative medicine, and CRISPR engineering have advanced the development of promising new treatments for debilitating diseases across a broad range of research areas, including neurological and cardiovascular disease, vision loss, and certain types of cancers. However, one of the biggest challenges with stem cell research is the high variability found within the development and manufacturing process that impacts the ability of the stem cells to differentiate and function. The new nCounter Stem Cell Characterization panel measures the eight essential components of stem cell biology and provides a novel, standardized assay for evaluating factors that influence and determine viability, functionality, and pluripotency.

"The simple, automated workflow and highly reproducible, digital results make the nCounter system an excellent fit for all types of stem cell applications," said Chad Brown, senior vice president of Sales and Marketing at NanoString. "With this panel, researchers have a powerful new tool that can quickly assess stem cell health to advance development efforts and optimize stem cell production, achieving robust results in less than 24 hours."

"The Process Development team at ARMI-BioFabUSA is very excited to use the nCounter Stem Cell Characterization panel across a number of our projects where we are developing human tissues composed of mature cells differentiated from stem cells. The Stem Cell Characterization Panel will give us greater insight into the differentiation status of our cells and the success of our current process development and manufacturing runs," said Damian Hile, senior process development scientist at Advanced Regenerative Manufacturing Institute-BioFabUSA (ARMI-BioFabUSA).

The novel 770 gene panel is available for humans and mice and was designed at NanoString with input from leading stem cell experts. To learn more about the nCounter Stem Cell Characterization Panel, visit NanoString at the virtual 2021 ISSCR Conference June 21-26. In addition, NanoString is sponsoring the Cellular Identity: Pluripotency Dynamics session, with Joseph Beechem, Ph.D., chief scientific officer at NanoString.

To learn more about the panel and how the development of the panel can expedite stem cell research, visit the Brief nCounters stem cell experience.

About ARMI-BioFabUSA

The Advanced Regenerative Manufacturing Institute (ARMI), headquartered in Manchester, NH, is an organization funded by the United States Department of Defense. ARMI's mission is to make practical the large-scale manufacturing of engineered tissues and tissue-related technologies to benefit existing industries and grow new ones. ARMI brings together a consortium of over 150 partners from across the industry, government, academia and the non-profit sector to develop next-generation manufacturing processes and technologies for cells, tissues and organs. For more information on ARMI-BioFabUSA, please visit http://www.ARMIUSA.org.

About NanoString Technologies, Inc.

NanoString Technologies is a leading provider of life science tools for discovery and translational research. The company's nCounter Analysis System is used in life sciences research and has been cited in more than 4,300 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's GeoMx Digital Spatial Profiler enables highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections.

For more information, please visit http://www.nanostring.com.

NanoString, NanoString Technologies, the NanoString logo, GeoMx, and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.

Read more:
NanoString Launches nCounter Stem Cell Characterization Panel to Advance the Development of Stem Cell Therapy - Business Wire

Adipose Tissue Derived Stem Cell Therapy Market study by The Insight Partners provides details about the market dynamics affecting the market, Market scope, Market segmentation and overlays shadow upon the leading market players highlighting the favorable competitive landscape and trends prevailing over the years.

The research report provides deep insights into the global market revenue, parent market trends, macro-economic indicators, and governing factors, along with market attractiveness per market segment. The report provides an overview of the growth rate of the Adipose Tissue Derived Stem Cell Therapy market during the forecast period, i.e., 20212028. Most importantly, the report further identifies the qualitative impact of various market factors on market segments and geographies. The research segments the market to offer more clarity regarding the industry, the report takes a closer look at the current status of various factors including but not limited to supply chain management, niche markets, distribution channel, trade, supply, and demand and production capability across different countries.

The report profiles the key players in the industry, along with a detailed analysis of their individual positions against the global landscape. The study conducts SWOT analysis to evaluate strengths and weaknesses of the key players in the Adipose Tissue Derived Stem Cell Therapy market. The researcher provides an extensive analysis of the Adipose Tissue Derived Stem Cell Therapy market size, share, trends, overall earnings, gross revenue, and profit margin to accurately draw a forecast and provide expert insights to investors to keep them updated with the trends in the market.

Get Sample Report of Adipose Tissue Derived Stem Cell Therapy Market Report @ https://www.theinsightpartners.com/sample/TIPRE00014843/

(*If you have any special requirements, please let us know and we will offer you the report as you want.)

The Adipose Tissue-derived Stem Cell Therapy Market is growing due to increasing use of regenerative medicine in disease treatment and increasing private and public funding for stem cell therapy. However, high cost associated with stem cell processing hampers growth of this market.

Competitive scenario:

The study assesses factors such as segmentation, description, and applications of Adipose Tissue Derived Stem Cell Therapy industries. It derives accurate insights to give a holistic view of the dynamic features of the business, including shares, profit generation, thereby directing focus on the critical aspects of the business.

The final report will add the analysis of the Impact of Covid-19 in this report Adipose Tissue Derived Stem Cell Therapy Market.

Adapting to the recent novel COVID-19 pandemic, the impact of the COVID-19 pandemic on the global Adipose Tissue Derived Stem Cell Therapy Market is included in the present report. The influence of the novel coronavirus pandemic on the growth of the Adipose Tissue Derived Stem Cell Therapy Market is analyzed and depicted in the report.

Some of the companies competing in the Adipose Tissue Derived Stem Cell Therapy Market are

Segmentation

The Adipose Tissue-derived Stem Cell Therapy market is segmented on the basis of cell type, product, disease and end user. Based on cell type, the market is segmented as autologous stem cells, allogeneic stem cells. On the basis of product, the market is categorized as cell line and culture media. Based on disease the market is segmented into cancer, obesity, wounds and injuries, musculoskeletal diseases, cardiovascular diseases and others. Based on end user the market is segmented into hospitals and trauma centers , cell banks and tissue banks , research laboratories and academic institutes and other The market is also segmented according to region. The Adipose Tissue Derived Stem Cell Therapy Market has been segmented into Latin America, North America, Asia Pacific, Europe, and the Middle East & Africa on the basis of region

Research Methodology

The report has its roots definitely set in thorough strategies provided by the proficient data analysts. The research methodology involves the collection of information by analysts only to have them studied and filtered thoroughly in an attempt to provide significant predictions about the market over the review period. The research process further includes interviews with leading market influencers, which makes the primary research relevant and practical. The secondary method gives a direct peek into the demand and supply connection. The market methodologies adopted in the report offer precise data analysis and provides a tour of the entire market. Both primary and secondary approaches to data collection have been used. In addition to these, publicly available sources such as SEC filings, annual reports, and white papers have been used by data analysts for an insightful understanding of the market. The research methodology clearly reflects an intent to extract a comprehensive view of the market by having it analyzed against many parameters. The valued inputs enhance the report and offer an edge over the peers.

Drivers & Constraints

The Adipose Tissue Derived Stem Cell Therapy Market rests united with the incidence of leading players who keep funding to the markets growth significantly every year. The report studies the value, volume trends, and the pricing structure of the market so that it could predict maximum growth in the future. Besides, various suppressed growth factors, restraints, and opportunities are also estimated for the advanced study and suggestions of the market over the assessment period.

Adipose Tissue Derived Stem Cell Therapy Market Segmented by Region/Country: North America, Europe, Asia Pacific, Middle East & Africa, and Central & South America

Interested in purchasing this Report? Click here @ https://www.theinsightpartners.com/buy/TIPRE00014843/

Thanks for reading this release; you can also customize this report to get select chapters or region-wise coverage with regions such as Asia, North America, and Europe.

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact US:

Call: +1-646-491-9876

Email: sales@theinsightpartners.com

View original post here:
Adipose Tissue Derived Stem Cell Therapy Market New Innovation and Perception 2028 AlloCure, Antria, Celgene, Cellleris SA, Corestem, Intrexon,...

REDWOOD CITY, Calif. and NEW YORK and BASEL, Switzerland, June 21, 2021 /PRNewswire/ --Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, andAruvant Sciences, a private company focused on developing gene therapies for rare diseases, today announced that they have entered a non-exclusive research collaboration to evaluate the use of JSP191, Jasper's anti-CD117 monoclonal antibody, as a targeted, non-toxic conditioning agent with ARU-1801, Aruvant's investigational lentiviral gene therapy for sickle cell disease (SCD). The objective of the collaboration is to evaluate the use of JSP191 as an effective and more tolerable conditioning agent that can expand the number of patients who can receive ARU-1801, a potentially curative treatment for SCD.

"This research collaboration with Aruvant is the first to use a clinical-stage antibody-based conditioning agent and a novel clinical-stage gene therapy, giving this combination a clear advantage by moving beyond the harsh conditioning agents currently used for gene therapy and establishing this next-generation potentially curative treatment as a leader in sickle cell disease," said Kevin N. Heller, M.D., executive vice president, research and development of Jasper. "Our goal is to establish JSP191 as a potential new standard of care conditioning agent, broadly in autologous gene therapy and allogeneic hematopoietic stem cell transplantation."

Gene therapies and gene editing technologies generally require that a patient's own hematopoietic stem cells first be depleted from the bone marrow to facilitate the engraftment of the new, gene-modified stem cells through a process called conditioning. Other investigational gene therapies and gene editing approaches in SCD use a high-dose chemotherapy such as busulfan for the conditioning regimen, which can place patients at prolonged risk for infection and bleeding, secondary malignancy and infertility. ARU-1801 is currently the only gene therapy that has demonstrated durable efficacy using both a lower dose of chemotherapy and a different agent than busulfan with a more limited side effect profile. The Aruvant-Jasper partnership is focused on evaluating the potential of using JSP191, a highly targeted anti-CD117 (stem cell factor receptor) monoclonal antibody agent, as the foundationof a novel conditioning regimen for use in combination with ARU-1801 to further reduce the negative side effects while maintaining efficacy.

"The unique attributes of ARU-1801 enable us to bring a potentially curative one-time therapy to individuals with sickle cell disease that can be delivered in the safest way possible," said Will Chou, M.D., Aruvant chief executive officer. "By partnering with Jasper to evaluate the use of JSP191 with ARU-1801, we are one step closer to developing a next-generation definitive therapy with an even more patient-friendly conditioning regimen. We believe that this combination may be able to further expand the number of patients who can benefit from ARU-1801 in the future, including potentially those with more moderate disease."

About JSP191 JSP191 is a humanized monoclonal antibody in clinical development as a conditioning agent that blocks stem cell factor receptor signaling leading to clearance of hematopoietic stem cells from bone marrow, creating an empty space for donor or gene-corrected transplanted stem cells to engraft. While hematopoietic cell transplantation can be curative for patients, its use is limited because standard high dose myeloablative conditioning is associated with severe toxicities and standard low dose conditioning has limited efficacy. To date, JSP191 has been evaluated in more than 90 healthy volunteers and patients. It is currently enrolling in two clinical trials for myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML) and severe combined immunodeficiency (SCID) and expects to begin enrollment in four additional studies in 2021 for severe autoimmune disease, sickle cell disease, chronic granulomatous disease and Fanconi anemia patients undergoing hematopoietic cell transplantation.

About ARU-1801 ARU-1801 is designed to address the limitations of current curative treatment options, such as low donor availability and the risk of graft-versus-host disease (GvHD) seen with allogeneic stem cell transplants. Unlike investigational gene therapies and gene editing approaches which require fully myeloablative conditioning, the unique characteristics of ARU-1801 allow it to be given with reduced intensity conditioning ("RIC"). Compared to myeloablative approaches, the lower dose chemotherapy regimen underlying RIC has the potential to reduce not only hospital length of stay, but also the risk of short- and long-term adverse events such as infection and infertility. Preliminary clinical data from the MOMENTUMstudy, an ongoing Phase 1/2 trial of ARU-1801 in patients with severe sickle cell disease, demonstrate continuing durable reductions in disease burden.

The MOMENTUM Study Aruvant is conducting the MOMENTUM study, which is evaluating ARU-1801, a one-time potentially curative investigational gene therapy for patients with SCD. This Phase 1/2 study is currently enrolling participants, and information may be found at momentumtrials.comwhich includes a patient brochure, an eligibility questionnaireand information for healthcare providers.

About Jasper Therapeutics Jasper Therapeutics is a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell. The company is advancing two potentially groundbreaking programs. JSP191, a first-in-class anti-CD117 monoclonal antibody, is in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. It is designed to enable safer and more effective curative allogeneic and autologous hematopoietic cell transplants and gene therapies. In parallel, Jasper Therapeutics is advancing its preclinical engineered hematopoietic stem cell (eHSC) platform, which is designed to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. Both innovative programs have the potential to transform the field and expand hematopoietic stem cell therapy cures to a greater number of patients with life-threatening cancers, genetic diseases and autoimmune diseases than is possible today. For more information, please visit us at jaspertherapeutics.com.

About Aruvant Sciences Aruvant Sciences, part of the Roivant family of companies, is a clinical-stage biopharmaceutical company focused on developing and commercializing gene therapies for the treatment of rare diseases. The company has a talented team with extensive experience in the development, manufacturing and commercialization of gene therapy products. Aruvant has an active research program with a lead product candidate, ARU-1801, in development for individuals suffering from sickle cell disease (SCD). ARU-1801, an investigational lentiviral gene therapy, is being studied in a Phase 1/2 clinical trial, the MOMENTUM study, as a one-time potentially curative treatment for SCD. Preliminary clinical data demonstrate engraftment of ARU-1801 and amelioration of SCD is possible with one dose of reduced intensity chemotherapy. The company's second product candidate, ARU-2801, is in development to cure hypophosphatasia, a devastating, ultra-orphan disorder that affects multiple organ systems and leads to high mortality when not treated. Data from pre-clinical studies with ARU-2801 shows durable improvement in disease biomarkers and increased survival. For more information on the ongoing ARU-1801 clinical study, please visit http://www.momentumtrials.comand for more on the company, please visit http://www.aruvant.com. Follow Aruvant on Facebook, Twitter @AruvantSciencesand on Instagram @Aruvant_Sciences.

About Roivant Roivant's mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity. Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch Vants nimble and focused biopharmaceutical and health technology companies. For more information, please visit http://www.roivant.com.

SOURCE Aruvant Sciences andJasper Therapeutics

https://www.aruvant.com

See the original post:
Jasper Therapeutics and Aruvant Announce Research Collaboration to Study JSP191, an Antibody-Based Conditioning Agent, with ARU-1801, a Novel Gene...

New York, June 23, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Nerve Repair and Regeneration Devices Industry" - https://www.reportlinker.com/p05957490/?utm_source=GNW The rapid rise in the incidence of nerve injuries worldwide, increasing prevalence of various neurological disorders, especially in the expanding elderly population, and development of advanced technology-based nerve repair and regeneration products are fueling growth in the global market. The constant increase in incidence of nerve injuries is leading to high demand for nerve repair and regeneration products. The growing incidence of chronic nervous system disorders such as Parkinson`s and Alzheimer`s disease is also driving demand for nerve repair and regeneration procedures and devices. There is also increased funding for clinical trials aimed at development of effective and safe therapies for treatment of various neurological disorders. Initiatives such as stem cells in umbilical blood infusion for cerebral palsy; and the use of Polyethylene glycol (PEG) drug for promoting axonal fusion technique for repairing peripheral nerve injuries are favoring market growth.

- Amid the COVID-19 crisis, the global market for Nerve Repair and Regeneration Devices estimated at US$6.6 Billion in the year 2020, is projected to reach a revised size of US$11.8 Billion by 2026, growing at a CAGR of 10% over the analysis period. Neurostimulation & Neuromodulation Devices, one of the segments analyzed in the report, is projected to grow at a 9.7% CAGR to reach US$10.9 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Biomaterials segment is readjusted to a revised 11.7% CAGR for the next 7-year period. This segment currently accounts for a 13.8% share of the global Nerve Repair and Regeneration Devices market. The neurostimulation and neuromodulation devices segment growth will be fueled by rising incidence of peripheral nerve injuries, development of technologically advanced products and favorable reimbursement scenario. Within the segment, internal neurostimulation and neuromodulation devices category is being driven due to the devices` ability to lower occurrence of post-surgical complications and reducing duration of hospitalization. Biomaterials segment is expected to witness high growth, driven by broadening application range, increased availability of government funding for innovations, and development of advanced products.

The U.S. Market is Estimated at $2.2 Billion in 2021, While China is Forecast to Reach $1.8 Billion by 2026

- The Nerve Repair and Regeneration Devices market in the U.S. is estimated at US$2.2 Billion in the year 2021. The country currently accounts for a 30.45% share in the global market. China, the world`s second largest economy, is forecast to reach an estimated market size of US$1.8 Billion in the year 2026 trailing a CAGR of 13% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.7% and 8.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.2% CAGR while Rest of European market (as defined in the study) will reach US$2 Billion by the end of the analysis period. Increasing incidence of neurological diseases and expanding geriatric population, increasing spending on healthcare sector, positive reimbursement framework and presence of several leading industry players are fueling growth in the North America region. Asia-Pacific is poised to grow at a robust pace, driven by sizeable patient pool, favorable healthcare initiatives and high unmet healthcare needs. The Asia-Pacific market is expected to gain from notable surge in aging population, increasing awareness regarding neurological disorders, and rising incidence of cancer and osteoporosis. Select Competitors (Total 61 Featured)

Read the full report: https://www.reportlinker.com/p05957490/?utm_source=GNW

CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW Impact of Covid-19 and a Looming Global Recession 2020 Marked as a Year of Disruption & Transformation EXHIBIT 1: World Economic Growth Projections (Real GDP, Annual % Change) for 2019 to 2022 Global Nerve Repair & Regeneration Market Buckles under COVID- 19 Strain Covid-19 Patients in Prone Position Suffering Nerve Damage Bodes Well for Market Growth Nerve Repair and Regeneration Market Set for a Robust Growth Neurostimulation & Neuromodulation Devices Hold Commanding Slot in Nerve Repair & Regeneration Market Biomaterials to Exhibit Rapid Growth Nerve Repair and Regeneration Market by Application US and Europe Dominate the Market Asia-Pacific and other Emerging Regions Display Impressive Growth Potential Recent Market Activity

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS High Incidence of Neurological Disorders: A Key Market Driver EXHIBIT 2: Annual Incidence of Adult-Onset Neurologic Disorders in the US Effects of COVID-19 on the Nervous System Sheds Focus on Neuromodulation Applications Increasing Cases of Peripheral Nerve Injuries Drive the Nerve Repair and Regeneration Market Growing Number of Vehicular Accidents Drive the Peripheral Nerve injuries Repair Market Rising Geriatric Population and Subsequent Growth in Prevalence of Neurological Disorders EXHIBIT 3: Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050 Growing Incidence of Neurodegenerative Diseases Propels the Market for Deep Brain Stimulation Devices EXHIBIT 4: Global Alzheimers Prevalence by Age Group EXHIBIT 5: Diagnosed Prevalence Cases of Parkinson?s Disease Across Select Countries EXHIBIT 6: Global DBS Market by Leading Player (2020E): Market Share Breakdown of Revenues for Medtronic, Boston Scientific, and Abbott Select Available Deep Brain Stimulation Devices Available in the Market Intensified Research Activity Across Various Neural Disciplines Induces Additional Optimism Stem Cell Therapy: A Promising Avenue for Nerve Repair and Regeneration Increasing Cases of Epilepsy Drives the Demand for Vagus Nerve Stimulation Devices EXHIBIT 7: Epilepsy Incidence by Type (2019): Percentage Share Breakdown for Idiopathic and Symptomatic Epilepsy EXHIBIT 8: Symptomatic Epilepsy Incidence by Type (2019): Percentage Share Breakdown of Congenital, Degenerative, Infective, Neoplastic, Trauma, and Vascular Epilepsy Spinal Cord Injuries Propel the Demand for Spinal Cord Stimulation Devices Recent Developments in Spinal Cord Injury Treatment Biomaterials (Nerve Conduits and Nerve Wraps) to Witness Rapid Growth New Biomaterials Pave the Way for Innovative Neurodegeneration Therapies Role of Nerve Conduits in the Treatment of Peripheral Nerve Injury Innovative Nerve Conduits from Stryker TENS (Transcutaneous electrical nerve stimulation devices) Market Witnesses Rapid Growth Non-Invasiveness of TMS (Transcranial Magnetic Stimulation) Propelling the adoption of TMS devices Nerve Grafts for Bridging Larger Nerve Gaps Role of Nerve Grafting in Treatment of Peripheral Nerve Injuries FDA-approved Nerve Tubes for Peripheral Nerve Repair

4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Nerve Repair and Regeneration Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Nerve Repair and Regeneration Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Nerve Repair and Regeneration Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Neurostimulation & Neuromodulation Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Neurostimulation & Neuromodulation Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Neurostimulation & Neuromodulation Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Biomaterials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Biomaterials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Biomaterials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Neurostimulation & Neuromodulation Surgeries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 11: World Historic Review for Neurostimulation & Neuromodulation Surgeries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Neurostimulation & Neuromodulation Surgeries by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Neurorrhaphy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 14: World Historic Review for Neurorrhaphy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Neurorrhaphy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Nerve Grafting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Nerve Grafting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Nerve Grafting by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Stem Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Stem Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Stem Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 23: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 26: World Historic Review for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 27: World 15-Year Perspective for Ambulatory Surgery Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES Table 28: USA Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 29: USA Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 30: USA 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 31: USA Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 32: USA Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 33: USA 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2020 & 2027

Table 34: USA Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 35: USA Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 36: USA 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2020 & 2027

CANADA Table 37: Canada Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 38: Canada Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 39: Canada 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 40: Canada Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 41: Canada Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 42: Canada 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2020 & 2027

Table 43: Canada Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 44: Canada Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 45: Canada 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2020 & 2027

JAPAN Table 46: Japan Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 47: Japan Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 48: Japan 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 49: Japan Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 50: Japan Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 51: Japan 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2020 & 2027

Table 52: Japan Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 53: Japan Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 54: Japan 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2020 & 2027

CHINA Table 55: China Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 56: China Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 57: China 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 58: China Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 59: China Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 60: China 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2020 & 2027

Table 61: China Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 62: China Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 63: China 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2020 & 2027

EUROPE Table 64: Europe Current & Future Analysis for Nerve Repair and Regeneration Devices by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 65: Europe Historic Review for Nerve Repair and Regeneration Devices by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 66: Europe 15-Year Perspective for Nerve Repair and Regeneration Devices by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027

Table 67: Europe Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 68: Europe Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 69: Europe 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 70: Europe Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 71: Europe Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 72: Europe 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2020 & 2027

Table 73: Europe Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 74: Europe Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 75: Europe 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2020 & 2027

FRANCE Table 76: France Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 77: France Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 78: France 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 79: France Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 80: France Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 81: France 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2020 & 2027

Table 82: France Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 83: France Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 84: France 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2020 & 2027

GERMANY Table 85: Germany Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 86: Germany Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 87: Germany 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 88: Germany Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

View post:
Global Nerve Repair and Regeneration Devices Market to Reach $11. 8 Billion by 2026 - GlobeNewswire

Sir, Andrew Mullen (Letters, July 21st) is in good company when he raises the issue of the legitimacy of the creation story.

Science has made huge steps forward in the last 50 years, with the field of molecular genetics emerging from the realization that DNA and RNA (ribonucleic acid) constitute the genetic material in all living things.

The Human Genome Project, the worlds largest collaborative biology research project, completed in April 2003, was headed up by Francis Collins.

His previous research projects involved the discovery of the genes that cause cystic fibrosis, cancer tumour growth and Huntington chorea, a neurological disease.

As a scientist, he has this to say on the creation story: The God of the Bible is also the God of the genome. He can be worshipped in a cathedral or in the laboratory. His creation is majestic, awesome, intricate, and beautiful

Progressive science, it seems, favours worship over mockery and ridicule. Yours, etc,

SEAMUS OCALLAGHAN,

Carlow.

Sir, Andrew Mullens letter is valid up to a point. He has the right to his own opinion regarding creation. Edwin Poots, et al, should not be ridiculed. If they want to believe the Genesis story as literal and historical, let them. They are harmless as long as they do not impose their ideas on others. Science and modern Christian theology agree that creation began around 13.7 billion years ago and what we observe now is the result of evolution. There is no point in arguing with creationists as they already know who God is. Yours, etc,

PAT COURTNEY,

Kilmyshall,

Wexford.

A chara, In claiming that a culture of intolerance ridicules and mocks normal Christian beliefs, Andrew Mullen seeks to defend Edwin Pootss creationist viewpoint.

As an atheist, I have no quarrel with any individuals beliefs but the record of politicians dictating what is acceptable through legislation is fairly dismal.

Not so long ago, the religious beliefs of certain politicians ensured that people in same-sex relationships or who got pregnant without being married were, at the very least, culturally unacceptable and, at worst, liable to prosecution.

Belief in mindless tradition and irrational superstition is grand as long as it is kept private. Is mise,

GREG SCANLON,

Shannon,

Co Clare.

Read more:
In the beginning science and faith - The Irish Times